Novartis Del-Brax Shows Breakthrough Potential in FSHD
BASEL, Switzerland, June 11, 2026 Novartis has announced positive results from the FORTITUDE Phase I/II clinical study evaluating delpacibart...
neuromuscular disease
Advertisement
ARTHEx Biotech Advances ATX-01 for Myotonic Dystrophy
VALENCIA, Spain, May 27, 2026 ARTHEx Biotech, a clinical-stage biotechnology company focused on RNA-based therapeutics for neuromuscular diseases, has...
CureDuchenne and Tevard Biosciences Advance DMD Therapy
NEWPORT BEACH, Calif., May 20, 2026 CureDuchenne announced a new partnership expansion with Tevard Biosciences to accelerate development of...
Atossa Therapeutics Highlights (Z)-Endoxifen Potential in Duchenne Muscular Dystrophy Research
SEATTLE, May 20, 2026 Atossa Therapeutics announced that a new scientific manuscript exploring the utrophin-modulation potential of (Z)-endoxifen in...
GEMMABio Expands Gene Therapy Pipeline for Rare Diseases
PHILADELPHIA, May 14, 2026 GEMMA Biotherapeutics (GEMMABio) unveiled its new Duchenne muscular dystrophy (DMD) gene therapy program and presented...
Advertisements
AskBio Expands Rare Disease Pipeline With AB-1009 Pompe Trial Milestone
DURHAM, N.C., May 11, 2026 AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary...
Solid Biosciences Licenses AAV-SLB101 Capsid to Advance Gene Therapies
CHARLESTOWN, Mass., Sept. 23, 2025 — Solid Biosciences has entered a non-exclusive licensing agreement with Kinea Bio to utilize...
Advertisement
